Bradford Whitmore Biography and Net Worth

Major Shareholder of Clearside Biomedical

Bradford T. Whitmore serves as Independent Chairman of the Board of the Company. Mr. Whitmore has been a director of the Company since June 2007 and Chair of our Board of Directors since March 2010. Since 1985, he has been the Managing Partner of Grace Brothers LP, an investment firm that holds approximately 3% of the outstanding shares of our common stock. Mr. Whitmore and Grace Brothers LP collectively hold or claim beneficial ownership of 34.9% of the outstanding shares of our common stock. Mr. Whitmore has a BS in Mechanical Engineering from Purdue University and an MBA from Northwestern University’s J.L. Kellogg Graduate School of Management. Over the past five years, Mr. Whitmore has served as a director of several privately held companies in which Grace Brothers LP and its affiliates held investments as well as not-for-profit organizations. Mr. Whitmore has been nominated for re-election to our Board of Directors because of his corporate development expertise and significant expertise in corporate financial matters.

What is Bradford T. Whitmore's net worth?: The estimated net worth of Bradford T. Whitmore is at least $387.69 thousand as of August 19th, 2025. Mr. Whitmore owns 1,085,965 shares of Clearside Biomedical stock worth more than $387,690 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Whitmore may own. Learn More about Bradford T. Whitmore's net worth.
How do I contact Bradford T. Whitmore?: The corporate mailing address for Mr. Whitmore and other Clearside Biomedical executives is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. Clearside Biomedical can also be reached via phone at (678) 270-3631 and via email at [email protected]. Learn More on Bradford T. Whitmore's contact information.
Has Bradford T. Whitmore been buying or selling shares of Clearside Biomedical?: Bradford T. Whitmore has not been actively trading shares of Clearside Biomedical during the last ninety days. Most recently, on Wednesday, February 7th, Bradford T. Whitmore bought 29,629 shares of Clearside Biomedical stock. The stock was acquired at an average cost of $20.25 per share, with a total value of $599,987.25. Following the completion of the transaction, the insider now directly owns 299,668 shares of the company's stock, valued at $6,068,277. Learn More on Bradford T. Whitmore's trading history.
Who are Clearside Biomedical's active insiders?: Clearside Biomedical's insider roster includes Richard Burke (Director), Thomas Ciulla (Insider), Charles Deignan (CFO), George Lasezkay (CEO), and Bradford Whitmore (Major Shareholder). Learn More on Clearside Biomedical's active insiders.
Are insiders buying or selling shares of Clearside Biomedical?: In the last year, Clearside Biomedical insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $13,800.00. The most recent insider tranaction occured on February, 24th when Director Clay Thorp bought 1,000 shares worth more than $13,800.00. Insiders at Clearside Biomedical own 6.7% of the company. Learn More about insider trades at Clearside Biomedical.
Information on this page was last updated on 2/24/2025.

Bradford T. Whitmore Insider Trading History at Clearside Biomedical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2024	Buy	29,629	$20.25	$599,987.25	299,668
11/1/2023	Buy	4,291	$11.10	$47,630.10	270,039
10/30/2023	Buy	40	$10.35	$414.00	261,027
9/1/2021	Sell	14,213	$103.35	$1,468,913.55	235,323
8/30/2021	Sell	6,626	$105.90	$701,693.40	235,323
1/6/2021	Buy	23,383	$42.75	$999,623.25	235,323
12/24/2020	Buy	3,413	$29.25	$99,830.25	211,939
12/2/2020	Buy	3,593	$29.25	$105,095.25	208,526
11/24/2020	Buy	4,133	$24.75	$102,291.75	204,933
11/16/2020	Buy	4,133	$25.35	$104,771.55
8/12/2020	Buy	20,000	$24.45	$489,000.00	193,333

Bradford T. Whitmore Buying and Selling Activity at Clearside Biomedical

Clearside Biomedical Company Overview

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Today's Range

Now: $0.36

$0.37

$0.59

50 Day Range

MA: $3.24

$0.36

$4.40

2 Week Range

Now: $0.36

$0.37

$17.10

Volume

2,768,773 shs

Average Volume

152,333 shs

Market Capitalization

$1.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04